We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




European Nonprofit to Focus on Personalized Medicine and Diagnostics

By LabMedica International staff writers
Posted on 09 Nov 2009
A nonprofit launched in Europe will focus on promoting and harmonizing personalized medicine and implementing "high value" diagnostics across the continent.

The European Personalized Medicine Diagnostics Association (EPEMED; Nantes, France), a membership association formed in August 2009 as a not-for-profit organization, will provide a platform for harmonization in the development and implementation of value-based diagnostics across Europe, to make personalized medicine a reality. More...
Personalized Medicine refers to the use of a person's clinical, genetic, genomic, and environmental information to select more precisely and accurately treatment for each individual patient. Its aims are to improve care and lower costs.

The central goals of EPEMED are to move personalized medicine forward throughout Europe through targeted education, idea sharing, and business models. The group plans to create joint programs with other international personalized medicine organizations, and to offer opinions on policies related to the field.

EPEMED appointed experts in the field of personalized medicine and molecular diagnostics as its founding board of directors. They include executives from Ipsogen (Marseilles, France), Genzyme Genetics (Cambridge, MA, USA), the Personalized Medicine Coalition (Washington, DC, USA), Theranostics (Rockville, MD, USA), and Novartis Molecular Diagnostics (East Hanover, NJ, USA), as well as from academic and institutional researchers, other businesses, and patient advocacy groups.

"The next few years will see deep changes in medical care due to the development of breakthrough innovations in the field of molecular diagnostics that will help clinicians in better treating their patients," Alain Huriez, founder and chairman of EPEMED, said in a statement. "It is our responsibility to make sure that these innovations will be made available to European patients and as a result, to make Europe an attractive place for innovations, financial and industrial investments in the area of personalized medicine diagnostics."

Related Links:

European Personalised Medicine Diagnostics Association
Ipsogen
Genzyme Genetics
Personalized Medicine Coalition
Theranostics
Novartis Molecular Diagnostics


New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Collection and Transport System
PurSafe Plus®
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.